Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2010

View Archived Issues

Vardenafil improves exercise capacity in phase III trial in subjects with PAH

New dual mTOR/PI3K-alpha inhibitor PF-04979064 may advance to clinic as anticancer agent

MEDI-578 has analgesic effects in rat model of inflammatory pain

New partial 5-HT3 receptor agonist described for treatment of IBS

Omecamtiv mecarbil improves left atrial contractility in healthy males

Vaxin and Stabilitech to collaborate in developing anthrax vaccine

Targacept describes new nicotinic acetylcholine receptor modulators

Shire reports highlights of second quarter 2010

Clinical data on sevuparin in healthy adults support evaluation in phase II trial in malaria

Santarus acquires rights to Rhucin and VLA-1-targeted antibody

Tekmira Pharma offers program update

Addex receives grant to support phase II trial of ADX-48621 for Parkinson's dyskinesia

AP-214 reduces development of acute kidney injury in phase II trial

FDA clarifies position on ProAmatine

Ono Pharma and Astellas submit minodronic acid MAA in Japan for osteoporosis

Advinus Therapeutics discovers new molecule for diabetes type 2

Genzyme to sell genetic testing business to LabCorp

Argenta and Genentech expand collaboration to include BioFocus

Cyclacel and FDA agree on a special protocol assessment for phase III sapacitabine trial

Forest Laboratories responds to FDA's complete response letter on roflumilast

XenoPort advances arbaclofen placarbil to phase III for spasticity in MS

Seattle Genetics discontinues lintuzumab development program

Merck & Co. identifies new muscarinic acetylcholine M1 receptor modulators

New CRFR-1 antagonists claimed by Emory University

Enanta Pharmaceuticals discloses novel inhibitors of HCV NS5

Ariad begins phase II trial of ponatinib in chronic myeloid leukemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...